Medtronic Invests $700 Mn in Cornerstone Robotics to Expand Robotic-Assisted Surgery

Under the new partnership, the investment includes rights for Medtronic to distribute the Sentire system in selected markets outside the US where it has regulatory approval.

Medtronic has entered a strategic partnership with Cornerstone Robotics, a Hong Kong-based surgical robotics company, through an investment of approximately $700 Mn, gaining rights to distribute the Sentire surgical system in select markets outside the US and expanding its global robotic-assisted surgery portfolio.

Sentire received CE Mark certification and Singapore Health Sciences Authority approval in May 2026 for minimally invasive general, gynecologic, thoracic, and urologic procedures. The system had previously received approval in China.

"Our strategy is focused on driving the next generation of minimally invasive surgery, one of our biggest growth opportunities," said Matt Anderson, senior vice president & president, Surgical, Medtronic. "Surgeons, health systems and markets have varying needs and preferences, which is why we are investing across robotic platforms, digital tools and platform-enhancing technologies. With Sentire complementing the Hugo RAS system, Medtronic will be the only company offering this two-platform portfolio combined with our surgical ecosystem—giving customers more access, more choice, and flexible solutions that fit their clinical and operational needs."

Sentire adds a complementary platform with an immersive console and dual-console capability. Cornerstone Robotics has developed the system through its in-house research and development capabilities, covering hardware, software, imaging, and other technologies.

"Since the founding of Cornerstone Robotics, we have been steadfast in our commitment to innovation, excellence, and clinical value," said Samuel Au, founder and CEO, Cornerstone Robotics. "We are confident physicians and patients alike will be the greatest beneficiaries of this partnership as we continue to expand access across this dynamic market."

Medtronic has been building its presence in the segment through Hugo, which is now used in more than 35 countries across six continents. The company expects procedures performed using Hugo to cross 50,000 globally by the end of its fiscal year.

Medtronic said Hugo will continue to receive software upgrades, expanded instrumentation, integrated stapling, and additional clinical capabilities.

Its wider surgical ecosystem also includes 3D visualization, wristed instruments and the Touch Surgery platform, alongside tools for robotics program optimization, training and service.

Stay tuned for more such updates on Digital Health News